share_log

Morgan Stanley Maintains Overweight on Maravai LifeSciences, Lowers Price Target to $11

Morgan Stanley Maintains Overweight on Maravai LifeSciences, Lowers Price Target to $11

摩根士丹利維持對Maravai LifeSciences的增持,將目標股價下調至11美元
Benzinga ·  2023/11/09 09:26

Morgan Stanley analyst Tejas Savant maintains Maravai LifeSciences (NASDAQ:MRVI) with a Overweight and lowers the price target from $12 to $11.

摩根士丹利分析師Tejas Savant維持Maravai LifeSciences(納斯達克股票代碼:MRVI)增持 “增持”,並將目標股價從12美元下調至11美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論